AR084102A1 - Comprimido farmaceutico que comprende el solvato de dimetilsulfoxido de la n-{3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenil}acetamida, su uso para preparar un medicamento util para tratar el cancer en un ser humano y procedimiento para preparar dichos comprimidos - Google Patents

Comprimido farmaceutico que comprende el solvato de dimetilsulfoxido de la n-{3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenil}acetamida, su uso para preparar un medicamento util para tratar el cancer en un ser humano y procedimiento para preparar dichos comprimidos

Info

Publication number
AR084102A1
AR084102A1 ARP110104773A ARP110104773A AR084102A1 AR 084102 A1 AR084102 A1 AR 084102A1 AR P110104773 A ARP110104773 A AR P110104773A AR P110104773 A ARP110104773 A AR P110104773A AR 084102 A1 AR084102 A1 AR 084102A1
Authority
AR
Argentina
Prior art keywords
prepare
compressed
dimethyl
trioxo
iodo
Prior art date
Application number
ARP110104773A
Other languages
English (en)
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46314827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR084102(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of AR084102A1 publication Critical patent/AR084102A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Comprimido farmacéutico que comprende: a) una cantidad de fármaco, que es el solvato de dimetilsulfóxido de la N{3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2H-pirido[4,3-d]pirimidin-1-il]fenil}acetamida, seleccionada entre 0,5635 mg y 2,254 mg; en el que el comprimido contiene de 25% a 89% en peso de uno o más excipientes, en el que los excipientes carecen sustancialmente de agua y la cantidad de fármaco no solvatado no supera 20%. Los excipientes se seleccionan entre: celulosa microcristalina, celulosa en polvo, almidón pregelatinizado, almidón, lactosa, fosfato dicálcico, lactitol, manitol, sorbitol y maltodextrina. Su uso para preparar un medicamento útil para tratar el cáncer en un ser humano. Procedimiento para preparar dichos comprimidos.
ARP110104773A 2010-12-20 2011-12-19 Comprimido farmaceutico que comprende el solvato de dimetilsulfoxido de la n-{3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenil}acetamida, su uso para preparar un medicamento util para tratar el cancer en un ser humano y procedimiento para preparar dichos comprimidos AR084102A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201061424967P 2010-12-20 2010-12-20

Publications (1)

Publication Number Publication Date
AR084102A1 true AR084102A1 (es) 2013-04-24

Family

ID=46314827

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP110104773A AR084102A1 (es) 2010-12-20 2011-12-19 Comprimido farmaceutico que comprende el solvato de dimetilsulfoxido de la n-{3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenil}acetamida, su uso para preparar un medicamento util para tratar el cancer en un ser humano y procedimiento para preparar dichos comprimidos
ARP210101433A AR122185A2 (es) 2010-12-20 2021-05-27 Comprimido farmacéutico que comprende el solvato de dimetilsulfóxido de la n-3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenilacetamida, su uso para preparar un medicamento útil para tratar el cáncer en un ser humano y procedimiento para preparar dichos comprimidos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP210101433A AR122185A2 (es) 2010-12-20 2021-05-27 Comprimido farmacéutico que comprende el solvato de dimetilsulfóxido de la n-3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenilacetamida, su uso para preparar un medicamento útil para tratar el cáncer en un ser humano y procedimiento para preparar dichos comprimidos

Country Status (37)

Country Link
US (5) US8580304B2 (es)
EP (4) EP4159204B1 (es)
JP (2) JP6126014B2 (es)
KR (1) KR101911109B1 (es)
CN (1) CN103998041B (es)
AR (2) AR084102A1 (es)
AU (1) AU2011349422B2 (es)
BR (1) BR112013015602B1 (es)
CA (1) CA2822701C (es)
CL (1) CL2013001779A1 (es)
CR (1) CR20130352A (es)
CY (1) CY1123376T1 (es)
DK (3) DK2654736T3 (es)
DO (1) DOP2013000138A (es)
EA (1) EA025198B1 (es)
ES (1) ES2820536T3 (es)
FI (2) FI4159204T3 (es)
HR (2) HRP20240563T1 (es)
HU (3) HUE066526T2 (es)
IL (1) IL226855A (es)
JO (1) JO3594B1 (es)
LT (3) LT2654736T (es)
MA (1) MA34883B1 (es)
MX (1) MX2013007073A (es)
MY (1) MY170501A (es)
NZ (1) NZ612157A (es)
PE (1) PE20140040A1 (es)
PL (3) PL2654736T3 (es)
PT (3) PT4159204T (es)
RS (2) RS65497B1 (es)
SG (1) SG191054A1 (es)
SI (3) SI2654736T1 (es)
TW (1) TWI505828B (es)
UA (1) UA113158C2 (es)
UY (1) UY33818A (es)
WO (1) WO2012088033A2 (es)
ZA (1) ZA201304189B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2884979T (pt) 2012-08-17 2019-09-04 Hoffmann La Roche Terapêuticas combinadas para o melanoma, compreendendo a administração de cobimetinib e vemurafinib
IL266415B2 (en) * 2012-11-30 2024-03-01 Glaxosmithkline Llc Innovative pharmaceutical composition
WO2015019125A1 (en) * 2013-08-05 2015-02-12 Societe De Developpement Et De Recherche Industrielle Molecular targets for the treatment of wounds, in particular chronic wounds
CN103819471A (zh) * 2013-11-25 2014-05-28 镇江圣安医药有限公司 吡啶并(4,3-d)嘧啶-1（2H）-基苯基乙酰胺的衍生物及其应用
WO2015081566A1 (zh) * 2013-12-06 2015-06-11 杭州普晒医药科技有限公司 曲美替尼及其溶剂化物的晶型、其制备方法、含有它们的药物组合物及其用途
EP2913048A1 (en) * 2014-02-27 2015-09-02 ratiopharm GmbH Pharmaceutical composition comprising trametinib
WO2016126012A1 (en) * 2015-02-05 2016-08-11 Boryung Pharmaceutical Co., Ltd Tablet and method of preparing the same
KR101545268B1 (ko) 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
US20170020880A1 (en) * 2015-07-22 2017-01-26 Hetero Research Foundation Pharmaceutical compositions of trametinib
BR112019002007B1 (pt) * 2016-08-10 2024-01-16 F. Hoffmann-La Roche Ag Composição farmacêutica e uso de uma composição farmacêutica
RU2627692C1 (ru) 2016-10-10 2017-08-10 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2
JP2019535696A (ja) * 2016-11-25 2019-12-12 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． ピリドン誘導体の医薬組成物およびその製造方法
PT3618875T (pt) 2017-05-02 2023-08-07 Novartis Ag Terapia de combinação que compreende um inibidor de raf e trametinib
US20220241258A1 (en) 2019-07-11 2022-08-04 Praxis Precision Medicines, Inc. Formulations of t-type calcium channel modulators and methods of use thereof
US20220354951A1 (en) 2019-08-02 2022-11-10 Onehealthcompany, Inc. Treatment of Canine Cancers
RU2749719C1 (ru) * 2020-10-08 2021-06-16 Нестерук Владимир Викторович Препарат для лечения анемии, связанной с хроническим заболеванием почек, и способ его получения
WO2023105286A1 (en) 2021-12-06 2023-06-15 My Personal Therapeutics Ltd A combination treatment for cancer
WO2024171019A1 (en) * 2023-02-13 2024-08-22 Alembic Pharmaceuticals Limited Pharmaceutical composition of trametinib and process of preparation thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61205257A (ja) * 1985-03-08 1986-09-11 Ishihara Sangyo Kaisha Ltd ベンゾイルウレア系化合物、その製法及びそれを含有する抗ガン剤
US4727077A (en) 1985-02-20 1988-02-23 Ishihara Sangyo Kaisha Ltd. Benzoyl urea compounds, process for their production, and antitumorous compositions containing them
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6825180B2 (en) 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
SI1761528T1 (sl) * 2004-06-11 2008-06-30 Japan Tobacco Inc 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2H-pirido(2,3-D)pirimidinski derivati in sorodne spojine za zdravljenje raka
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
US7955622B2 (en) * 2006-10-13 2011-06-07 Actavis Group Ptc Hf Controlled-release galantamine formulations
CA2668724A1 (en) * 2006-11-09 2008-05-22 Gilead Colorado, Inc. Darusentan oral dosage form
JO2985B1 (ar) * 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
CA2694646C (en) * 2007-07-30 2017-09-05 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
WO2009042803A1 (en) * 2007-09-25 2009-04-02 Teva Pharmaceutical Industries Ltd. Imatinib compositions
CN104530061B (zh) * 2008-07-08 2017-05-10 贝达药业股份有限公司 埃克替尼盐酸盐晶型、药物组合物和用途
CN102770026B (zh) 2009-09-23 2015-04-01 葛兰素史密斯克莱有限责任公司 组合
EP2480085B1 (en) 2009-09-23 2014-11-12 GlaxoSmithKline LLC Combination comprising the MEK inhibitor N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo- phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide and the Akt inhibitor N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1- methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide
KR20120099217A (ko) 2009-09-28 2012-09-07 글락소스미스클라인 엘엘씨 조합물
DK2488033T3 (da) 2009-10-16 2019-09-02 Novartis Ag Kombination, der omfatter en MEK-hæmmer og en B-raf-hæmmer
SG10201407558TA (en) 2009-11-17 2015-01-29 Glaxosmithkline Llc Combination
JP5903433B2 (ja) 2010-08-26 2016-04-13 ノバルティス アーゲー 癌の治療に有用なｖｅｇｆｒ阻害剤およびｍｅｋ阻害剤の医薬的組み合わせ
US8977217B1 (en) 2013-02-20 2015-03-10 Triquint Semiconductor, Inc. Switching device with negative bias circuit

Also Published As

Publication number Publication date
US9399021B2 (en) 2016-07-26
HRP20201409T1 (hr) 2020-11-27
US9155706B2 (en) 2015-10-13
US20130266649A1 (en) 2013-10-10
PT2654736T (pt) 2020-09-24
JP2017137299A (ja) 2017-08-10
LT4159204T (lt) 2024-05-10
DK4159205T3 (da) 2024-05-13
SG191054A1 (en) 2013-08-30
EP4159204B1 (en) 2024-02-14
PL4159204T3 (pl) 2024-07-01
AU2011349422B2 (en) 2015-12-10
KR20130130028A (ko) 2013-11-29
PL4159205T3 (pl) 2024-06-24
TW201249441A (en) 2012-12-16
EP2654736A4 (en) 2015-04-22
MA34883B1 (fr) 2014-02-01
CN103998041B (zh) 2016-08-17
RS65496B1 (sr) 2024-06-28
PL2654736T3 (pl) 2020-12-14
DK2654736T3 (da) 2020-09-14
JP6126014B2 (ja) 2017-05-10
HRP20240563T1 (hr) 2024-08-16
AU2011349422A1 (en) 2013-05-02
PT4159205T (pt) 2024-05-08
BR112013015602B1 (pt) 2022-03-03
EP4159204A1 (en) 2023-04-05
EA201390913A1 (ru) 2014-04-30
CY1123376T1 (el) 2021-12-31
CA2822701A1 (en) 2012-06-28
US20140037726A1 (en) 2014-02-06
US8580304B2 (en) 2013-11-12
WO2012088033A3 (en) 2014-03-13
KR101911109B1 (ko) 2018-10-23
US20120183613A1 (en) 2012-07-19
FI4159204T3 (fi) 2024-04-22
BR112013015602A2 (pt) 2017-02-21
HUE066526T2 (hu) 2024-08-28
HUE066525T2 (hu) 2024-08-28
UA113158C2 (xx) 2016-12-26
PT4159204T (pt) 2024-05-07
WO2012088033A2 (en) 2012-06-28
US20140154316A1 (en) 2014-06-05
CA2822701C (en) 2018-10-23
MX2013007073A (es) 2013-09-26
SI4159205T1 (sl) 2024-06-28
LT4159205T (lt) 2024-05-10
CL2013001779A1 (es) 2014-06-27
EP4159205B1 (en) 2024-02-14
DK4159204T3 (da) 2024-05-21
EP2654736B1 (en) 2020-07-01
UY33818A (es) 2012-07-31
JO3594B1 (ar) 2020-07-05
ZA201304189B (en) 2014-02-26
MY170501A (en) 2019-08-08
EA025198B1 (ru) 2016-11-30
EP2654736A2 (en) 2013-10-30
JP2014510704A (ja) 2014-05-01
IL226855A (en) 2017-04-30
PE20140040A1 (es) 2014-02-26
NZ612157A (en) 2015-05-29
AR122185A2 (es) 2022-08-24
EP4159205A1 (en) 2023-04-05
RS65497B1 (sr) 2024-06-28
FI4159205T3 (fi) 2024-04-23
SI4159204T1 (sl) 2024-06-28
SI2654736T1 (sl) 2020-10-30
CN103998041A (zh) 2014-08-20
LT2654736T (lt) 2020-09-25
DOP2013000138A (es) 2013-11-30
US9271941B2 (en) 2016-03-01
US20140099365A1 (en) 2014-04-10
TWI505828B (zh) 2015-11-01
HUE050788T2 (hu) 2021-01-28
CR20130352A (es) 2013-12-18
EP3808343A1 (en) 2021-04-21
ES2820536T3 (es) 2021-04-21

Similar Documents

Publication Publication Date Title
AR084102A1 (es) Comprimido farmaceutico que comprende el solvato de dimetilsulfoxido de la n-{3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenil}acetamida, su uso para preparar un medicamento util para tratar el cancer en un ser humano y procedimiento para preparar dichos comprimidos
CL2016001411A1 (es) Unidad de dosificación farmacéutica solida de desintegración oral que comprende un componente de estetrol; metodo de preparación; uso para la anticoncepción femenina y en terápia de sustitución hormonal femenina.
CY1115652T1 (el) Μορφη δοσολογιας που περιεχει δυο δραστικα φαρμακευτικα συστατικα μειγματος σε διαφορετικες φυσικες μορφες
AR121359A2 (es) Un comprimido veterinario sólido que se comprime directamente a partir del polvo que no se sometió a una etapa de granulación, que comprende meloxicam o una de sus sales farmacéuticamente aceptables y excipientes
UA116334C2 (uk) Тверді форми дозування бендамустину
BRPI0513598A (pt) formas de dosagem em comprimidos revestidos de liberação entérica
CR11709A (es) Preparacion solida de desintegracion oral
MX2008012731A (es) Tabletas de paracetamol de liberacion rapida.
ES2574836T3 (es) Formulación de liberación prolongada de nevirapina
EA201590449A1 (ru) Перорально вводимая лекарственная композиция
CR20110704A (es) Composiciones de dosis fija farmacéuticas sólidas que comprenden irbesartán y amilodipina, su preparación y su aplicación terapéutica
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
PH12015500823A1 (en) Modified release formulations for oprozomib
CO6640305A2 (es) Elaboración de gránulos sin activos y tabletas que comprenden los mismos
HRP20180219T1 (hr) Sredstvo za uporabu u slučaju netolerancije na fruktozu
RU2016117186A (ru) Комбинированная композиция, содержащая тадалафил и амлодипин
AR097512A1 (es) Forma de dosis unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolítico que comprende darunavir y ritonavir
AR080256A1 (es) Formulaciones farmaceuticas solidas de ramipril y besilato de amlodipino y su preparacion
MX2017005163A (es) Composiciones de liberación prolongada de onapristona y métodos.
RU2017126111A (ru) Сложные капсулы, содержащие ралоксифен и витамин D и его производные
TR201007926A1 (tr) Prasugrel tablet formülasyonları.
PH12016502540A1 (en) Pharmaceutical dosage forms
GT200600242A (es) Formulaciones farmaceuticas de liberacion inmediata y con una carga de droga elevada de (4-clorofenil)[4-(4-piridilmetil)ftalazin-1-ilo] no micronizado, y sus sales
UA91281U (uk) Спосіб одержання фармацевтичного препарату, що має виражену антигестагенну дію
PE20221446A1 (es) Nuevas formulaciones de comprimido de fosfomicina

Legal Events

Date Code Title Description
FC Refusal